`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`BLUEBIRD BIO, INC.,
`Petitioner,
`
`v.
`
`SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH,
`Patent Owner.
`____________
`Case No. IPR2023-00074
`Patent No. 8,058,061
`____________
`
`
`
`
`PATENT OWNER’S MANDATORY NOTICE
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2023-00074
`Patent 8,058,061
`
`
`
`The named patent owner in the above-referenced proceeding, Sloan
`Kettering Institute for Cancer Research (“SKI” or the “Patent Owner”), by and
`through its exclusive licensee, provides this notice without waiving any of Patent
`Owner’s rights.
`SKI granted San Rocco Therapeutics, LLC (“SRT” or “Exclusive
`Licensee”), formerly known as Errant Gene Therapeutics, LLC, an exclusive
`license to U.S. Patent Nos. 7,541,179 (“the ’179 Patent”) and 8,058,061 (“the ’061
`Patent”). On October 19, 2022, the Patent Owner informed SRT that, as the
`exclusive licensee of the ’061 Patent, it expects SRT to defend the challenged
`claims at SRT’s expense. In response, on October 20, 2022, SRT affirmed its
`responsibility to defend the validity of the ’061 Patent at its own expense because
`SRT is the exclusive licensee pursuant to an exclusive license agreement with the
`Patent Owner.
`As the exclusive licensee to the ’061 Patent, SRT provides this notice
`without waiving any of the Patent Owner’s or SRT’s rights.
`1.
`Real Party in Interest (§ 42.8(b)(1)).
`The real parties in interest are SRT, located at 308 East Emily Street, Tampa,
`Florida 33603; SKI, located at 1275 York Avenue, New York, New York 10065; and
`Memorial Sloan-Kettering Cancer Center (“MSKCC”), located at 1275 York
`Avenue, New York, New York 10065.
`
`1
`
`
`
`Case IPR2023-00074
`Patent 8,058,061
`
`
`2.
`
`Related Matters (§ 42.8(b)(2)).
`A. Matters Involving Petitioner.
`On November 2, 2020, the Patent Owner granted SRT an exclusive license to
`the ’061 Patent. As a result of that exclusive license, SRT has the right to assert the
`’061 Patent against infringers and to defend the validity of the ’061 Patent before the
`Patent Trial and Appeal Board. On October 21, 2021, SRT filed a complaint against
`bluebird bio, Inc. (“bluebird”) in the District of Delaware alleging infringement of
`the ’179 and ’061 Patents. See Errant Gene Therapeutics, LLC v. Bluebird Bio, Inc.,
`1-21-cv-01478, (D. Del. October 21, 2021) (“Delaware Action”), D.I. 1. On
`November 17, 2021, SRT amended its complaint to include Third Rock Ventures,
`LLC (“TRV”) as a defendant alleging that TRV, knowingly and willfully, induced
`and continues to induce infringement of the ’061 Patent. See id., at D.I. 9.
`Subsequently, bluebird and TRV filed a motion to dismiss or, in the alterative, stay
`proceedings and compel arbitration. See id., at D.I. 15.
`In the Delaware Action, on July 26, 2022, Judge Richard G. Andrews granted,
`in part, bluebird and TRV’s motion to compel arbitration and denied their motion to
`dismiss SRT’s second amended complaint. Id., at D.I. 76. Specifically, Judge
`Andrews: (i) held that the court must determine whether SRT has constitutional and
`statutory standing following arbitration of threshold issues; and (ii) noted that his
`decision does not compel arbitration of SRT’s patent infringement claims. Id. SRT
`subsequently filed a Demand for Arbitration and Statement of Claim with the
`American Arbitration Association, and the arbitration has been assigned Case No.
`
`2
`
`
`
`Case IPR2023-00074
`Patent 8,058,061
`
`
`01-22-0003-6927. On October 18, 2022, Petitioner filed IPR2023-00070 against the
`’179 Patent and IPR2023-00074 (the instant action) against the ’061 Patent.
`B. Additional Matters Involving the ’061 Patent
`On October 5, 2021, SRT filed a complaint for declaratory judgment seeking
`a declaration that (i) recombinant vectors SNS23.B87.A1 and SNS23.2.B87.A1
`(collectively, the “SNS23 Vectors”) are covered by a claim of the ’179 and/or ’061
`Patents; and (ii) transduced cells containing SNS23 Vectors are covered by a valid
`claim of the ’179 and/or ’061 Patents. See Errant Gene Therapeutics, LLC v.
`
`Memorial Sloan-Kettering Cancer Center and Sloan Kettering Institute of Cancer
`Research, 1-21-cv-08206 (S.D.N.Y) (“SDNY Action”), D.I. 1. The SDNY Action
`is currently pending before Judge Vernon S. Broderick.
`C. Continuity and Priority.
`The ’179 and ’061 Patents claim priority to U.S. Provisional Application No.
`60/301,861 filed on June 29, 2001, U.S. Provisional Application No. 60/302,852
`filed on July 2, 2001, and U.S. Non-Provisional Application No. 10/188,221 (“the
`’221 Application”) filed on July 1, 2002. The ’061 Patent also claims priority to U.S.
`Non-Provisional Application No. 12/433,412, which is a divisional of the ’221
`Application and which was filed on April 30, 2009.
`
`3
`
`
`
`Case IPR2023-00074
`Patent 8,058,061
`
`
`3.
`
`Designation of Lead and Backup Counsel (§ 42.8(b)(3)).
`
`Lead Counsel
`Luke Toft (Reg. No. 75,311)
`ltoft@foxrothschild.com
`Fox Rothschild LLP
`33 South Sixth Street, Suite 3600
`Minneapolis, MN 55402
`Telephone: (612) 607-7000
`Facsimile: (612) 607-7100
`
`
`Backup Counsel
`Joe Chen (Reg. No. 70,066)
`joechen@foxrothschild.com
`Fox Rothschild LLP
`997 Lenox Drive
`Lawrenceville, NJ 08648
`Telephone: (609) 844-3024
`Facsimile: (609) 896-1469
`
`Additional counsel for SRT may seek pro hac vice admission for the IPR
`Proceeding referenced herein.
`4.
`Service Information.
`Service on the Patent Owner and Exclusive Licensee may be made by
`electronic mail to counsel at the email addresses above. Alternatively, service may
`be made by mail or hand delivery to: Fox Rothschild LLP, 33 South Sixth Street,
`Suite 3600, Minneapolis, MN 55402. The fax number for lead counsel is reflected
`above.
`
`4
`
`
`
`Case IPR2023-00074
`Patent 8,058,061
`
`
`
`Dated: November 8, 2022
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`By: /s/ Luke Toft
`Luke Toft (Reg. No. 75,311)
`FOX ROTHSCHILD LLP
`33 South Sixth Street, Suite 3600
`Minneapolis, MN 55402
`Telephone: (612) 607-7000
`Facsimile: (612) 607-7100
`ltoft@foxrothschild.com
`
`Joe Chen (Reg. No. 70,066)
`FOX ROTHSCHILD LLP
`997 Lenox Drive
`Lawrenceville, NJ 08648
`Telephone: (609) 844-3024
`Facsimile: (609) 896-1469
`joechen@foxrothschild.com
`
`Counsel for San Rocco Therapeutics, LLC
`
`5
`
`
`
`Case IPR2023-00074
`Patent 8,058,061
`
`
`
`CERTIFICATE OF SERVICE
`Pursuant to 37 CFR § 42.6(e), the undersigned hereby certifies that on
`
`November 8, 2022, the foregoing Patent Owner’s Mandatory Notice was served via
`
`e-mail, as authorized by the Petitioner, at the following email correspondence
`
`address of record:
`
`Naveen Modi
`Eric W. Dittmann
`Daniel Zeilberger
`Max H. Yusem
`Krystina L. Ho
`bluebird-IPR-PH@paulhastings.com
`
`PAUL HASTINGS LLP
`2050 M Street NW
`Washington, D.C. 20036
`
`Dated: November 8, 2022
`
`
`
`
`
`/s/ Luke Toft
`Luke Toft (Reg. No. 75,311)
`Counsel for San Rocco Therapeutics, LLC
`
`
`
`
`
`
`
`
`
`6
`
`